Axsome Therapeutics vs Oruka Therapeutics

Axsome Therapeutics (AXSM), health care, and Oruka Therapeutics (ORKA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Axsome Therapeutics is worth $7.2B on the stock market and Oruka Therapeutics $6.5B: Axsome Therapeutics is valued at 9% more. Over the past year Axsome Therapeutics's share price has moved -7.10% and Oruka Therapeutics's +262%.

Key facts

Axsome Therapeutics market value
$7.2B
Oruka Therapeutics market value
$6.5B
Axsome Therapeutics revenue
$638.5MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Axsome Therapeutics vs Oruka Therapeutics: every measure side by side
Measure Axsome Therapeutics Oruka Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.2Bhigher$6.5Blower
Revenue$638.5M—
Earnings-$183.2Mlower-$105.4Mhigher
Employees1,390higher68lower
Total assets$689.8Mhigher$488.6Mlower
Valuation
P/E——
P/S11.2—
P/B67.8higher5.4lower
Dividend yield0.00%0.00%
Profitability
Operating margin-26.1%—
Balance sheet
Net assets$88.3Mlower$471.9Mhigher
Total liabilities$601.5Mhigher$16.7Mlower
Total debt$187.7M—
Cash on hand$322.9Mhigher$46.9Mlower
Price change
Today-0.77%higher-2.94%lower
1 year-7.10%lower+262%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Axsome Therapeutics only (0)

None of the tracked investors.

Oruka Therapeutics only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns AXSM · Who owns ORKA

Further comparisons

Learn

Questions and answers

Which is bigger, Axsome Therapeutics or Oruka Therapeutics?

By market value, Axsome Therapeutics is the larger: $7.2B against $6.5B for Oruka Therapeutics.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Axsome Therapeutics and Oruka Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Axsome Therapeutics and 3 hold Oruka Therapeutics.

Cite this page

Funkfolio, “Axsome Therapeutics vs Oruka Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/axsm-vs-orka

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.